Decreased Blood Levels of Oxytocin in Ketamine-Dependent Patients During Early Abstinence.
Ming-Chyi Huang, Lian-Yu Chen, Hu-Ming Chang, Xiao-Yu Liang, Chih-Ken Chen, Wan-Ju Cheng, Ke Xu
Frontiers in Psychiatry 2018 DOI: 10.3389/fpsyt.2018.00633 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational case-control study Peer reviewed |
|---|---|
| Sample size | 130 |
| Population | 65 ketamine-dependent patients and 65 controls |
| Duration | Baseline assessment and 1- and 2-week follow-up after ketamine withdrawal |
| Measures | Beck Depression Inventory, Beck Anxiety Inventory (BAI), Visual Analog Scale for craving, Childhood Trauma Questionnaire-short form |
| Topics | Addiction Ketamine Esketamine |
| Keywords | Nmda antagonist Oxytocin Withdrawal |
| Key findings | Ketamine-dependent patients had lower baseline plasma oxytocin than controls (5.89 vs. 9.53 ng/mL), and levels rose only partially after one and two weeks of withdrawal, remaining below controls. The authors argue this suggests oxytocin system dysregulation following chronic ketamine abuse and a possible link between lower oxytocin and an anxious phenotype of dependence. |
Abstract
Background: Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is a common drug of abuse worldwide. Existing evidence suggest a disruption of oxytocin system involves in the development of addiction. In this study, we aimed to investigate the role of oxytocin in ketamine addiction by measuring the blood oxytocin levels in ketamine-dependent (KD) patients.
Methods: Sixty-five KD patients and 65 controls were enrolled. Fasting plasma levels of oxytocin were determined at baseline and 1 and 2 weeks after ketamine withdrawal. Ketamine use variables, Beck Depression Inventory, Beck Anxiety Inventory (BAI), Visual Analog Scale for craving, and Childhood Trauma Questionnaire-short form were assessed in KD patients.
Results: KD patients had significantly lower levels of oxytocin at baseline compared to controls (5.89 ± 2.13 vs. 9.53 ± 4.17 ng/mL, P < 0.001). Oxytocin levels increased after one (6.74 ± 2.63, P < 0.002) and 2 weeks (6.89 ± 2.69, P = 0.01) of withdrawal in KD patient despite the levels were still lower than controls (P = 0.001 and 0.002, respectively). The clinical variables did not correlate with baseline oxytocin levels except BAI scores, which showed a negative correlation with the levels (r = -0.263; P = 0.039).
Conclusion: We found a distinctively reduced oxytocin level in KD patients and the level did not normalize after early abstinence. Lower oxytocin might be associated with anxious phenotype of ketamine dependence. These results suggest that oxytocin system dysregulated following chronic ketamine abuse and might provide insight in evaluating the potential therapeutic use of oxytocin for treating ketamine dependence.
Comparable studies
Other observational and cohort studies on ketamine for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Brain damages in ketamine addicts as revealed by magnetic resonance imaging Ketamine addicts | 2014 | Observational cohort | n = 21 |
| Characterization of Oral Ketamine Use: A Retrospective Review. Hospitalized patients aged 18 years or older receiving oral ketamine | 2025 | Retrospective cohort study | |
| Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice. Patients receiving intramuscular ketamine with contemporaneous psychotherapy for... | 2024 | Observational study | n = 70 |
| Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance. Adults aged 18 years or older with major depressive disorder in the TriNetX US... | 2026 | Retrospective cohort study | n = 30,670 |
| Ketamine Therapy for Chronic Pain Provides Added Benefits for Substance Misuse Therapy Adult chronic pain patients with comorbid substance misuse | 2026 | Observational study | n = 20 |
Citations in the library
Cited by 4
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing CNS Drugs February 14, 2022
- The psychedelic-peptide paradox: a hormetic hypothesis. Comprehensive Psychoneuroendocrinology June 2, 2025
- Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study. Pharmaceuticals April 25, 2025
Cites 5
- Ketamine use: a review Addiction July 21, 2011
- To use or not to use: an update on licit and illicit ketamine use Substance Abuse and Rehabilitation March 1, 2011
- Comparison of illegal drug use pattern in Taiwan and Korea from 2006 to 2014 Substance Abuse Treatment, Prevention, and Policy September 23, 2016
- Potential benefit of lamotrigine in managing ketamine use disorder. Medical Hypotheses February 1, 2016
- The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging health threats journal April 15, 2011